Amneal Pharmaceuticals has received FDA approval for the generic tramadol hydrochloride oral formulation, tapping into a high-demand asset used for managing moderate to moderately severe pain. This clearance is expected to drive competitive pricing and begin eroding United Therapeutics’ current market share in this financially significant pain management segment.